CENTURY THERAPEUTICS INC

Century Therapeutics’ insider buying and bullish market buzz reveal executives’ confidence in its stem‑cell oncology pipeline, highlighting key payer, digital‑trial, and manufacturing strategies that could boost investor returns.

Century Therapeutics insider sale: Gregory sells 524 shares at $2.11, a routine move that signals stable confidence amid promising preclinical data and market volatility.

Century Therapeutics’ new 88k option grant signals confidence in its adult‑stem‑cell platform; insider sales are routine, so focus on upcoming trials and FDA milestones for future upside.

Century Therapeutics insider sales reveal routine tax‑withholding moves, showing stable management holdings amid biotech volatility and stem‑cell pipeline progress.

Insider sales at Century Therapeutics are routine tax‑withholding moves, not a red flag—highlighting steady executive liquidity management amid solid cash flow and advancing clinical programs.

Century Therapeutics insider sales reveal routine liquidity moves, not big upside bets, underscoring a focus on cell‑therapy milestones rather than market‑price tricks.

Century Therapeutics CEO’s March 6 sale: a routine tax‑compliance move, not a signal of weakness, underscoring the company’s steady stem‑cell pipeline and long‑term investor confidence.

CEO sells 463 shares of Century Therapeutics on March 6, 2026, a tax‑driven move that doesn’t signal a sell‑off; insider confidence and strong revenue growth point to cautious optimism.

Insider sale: Carr Douglas sells 323 shares of Century Therapeutics for $1.82 each – a tax‑triggered move that leaves his stake stable amid a volatile, high‑risk stem‑cell biotech landscape and upcoming regulatory milestones.